Targeting ESR1 mutation–induced transcriptional addiction in breast cancer with BET inhibition

Acquired mutations in the ligand-binding domain (LBD) of the gene encoding estrogen receptor α (ESR1) are common mechanisms of endocrine therapy resistance in patients with metastatic ER(+) breast cancer. The ESR1 Y537S mutation, in particular, is associated with development of resistance to most en...

Descripción completa

Detalles Bibliográficos
Autores principales: Udden, Sm N., Wang, Qian, Kumar, Sunil, Malladi, Venkat S., Wu, Shwu-Yuan, Wei, Shuguang, Posner, Bruce A., Geboers, Sophie, Williams, Noelle S., Liu, Yulun, Sharma, Jayesh K., Mani, Ram S., Malladi, Srinivas, Parra, Karla, Hofstad, Mia, Raj, Ganesh V., Larios, Jose M., Jagsi, Reshma, Wicha, Max S., Park, Ben Ho, Gupta, Gaorav P., Chinnaiyan, Arul M., Chiang, Cheng-Ming, Alluri, Prasanna G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536271/
https://www.ncbi.nlm.nih.gov/pubmed/35881485
http://dx.doi.org/10.1172/jci.insight.151851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536271/
https://www.ncbi.nlm.nih.gov/pubmed/35881485
http://dx.doi.org/10.1172/jci.insight.151851

Ejemplares similares